482740

nNOS - PSD-95 Interaction Inhibitor, ZL006

The nNOS - PSD-95 Interaction Inhibitor, ZL006 controls the biological activity of nNOS. This small molecule/inhibitor is primarily used for Cancer applications.

• Sinónimos: nNOS - PSD-95 Interaction Inhibitor, ZL006, 5-(3,5-dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid
• Fórmula empírica (notación de Hill): C₁₄H₁₁Cl₂NO₄
• Peso molecular: 328.15
• MDL number: MFCD20527326
• UNSPSC Code: 12352200
• NACRES: NA.32

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; protect from light
• color: off-white
• solubility: DMSO: 50 mg/mL
• shipped in: ambient
• storage temp.: −20°C

Descripción

General description

A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neuron cultures (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment before 30 min Glu-Gly stimulation) in vitro and in mice subjected to middle brain artery occlusion (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before MACO; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents) in rat hippocampus. Its therapeutic efficacy in limiting ischemia-caused brain tissue damage has been demonstrated in both mice and rats when applied 1 h after blood reperfusion following MACO (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).

A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neurons (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment) in vitro and in mice (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before ischemia; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents). Effectively reduce ischemia-caused brain tissue damage in both mice and rats when applied 1 h after blood reperfusion following ishemia (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).

Packaging

Packaged under inert gas

Warning

Toxicity: Regulatory Review (Z)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Zhou, L., et al. 2010. Nature Med.16, 1439.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3